Descartes-08

Verified

Overview

Descartes-08 is a cell therapy wherein T-cells are modified to attack myeloma cells. To modify the cells, new instructions (called RNA) are inserted into the T-cells. These RNA instructions cause the CAR in Descartes-08 T-cells to kill other cells that carry a marker called BCMA. Because the BCMA marker is present on myeloma cells, it is hoped that Decartes-08 will destroy the myeloma cells without harming most other cell types.

Descartes-08 CAR-T cells are altered with RNA, which has a defined half-life. This allows the cells to be administered repetitively in large numbers to kill myeloma cells. It also allows CAR T-cell numbers in the body to be predictable and controlled, potentially reducing risk of side effects.

SparkCures ID 321
Developed By Cartesian Therapeutics
Generic Name Descartes-08
Treatment Classifications
Treatment Targets

Clinical Trials

All Clinical Trials

View all active clinical trials around the US.

Late Relapse Multiple Myeloma

The following is a listing of clinical trials for patients with multiple myeloma who have received three or more prior lines of therapy.

Smoldering Myeloma
Monoclonal Gammopathy of Undetermined Significance (MGUS)

Resources

There are no resources, links or videos to display for this treatment.

SparkCures Verified

SparkCures is working closely with Cartesian Therapeutics to provide the most up-to-date information on this treatment. Use the button above to add this treatment to your list of favorites.

Learn more about how we work with industry partners